6,627 Shares in Biogen Inc. $BIIB Purchased by Vise Technologies Inc.

Vise Technologies Inc. bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,627 shares of the biotechnology company’s stock, valued at approximately $1,432,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Biogen in the 2nd quarter worth approximately $3,453,878,000. Norges Bank acquired a new position in shares of Biogen in the fourth quarter worth about $464,408,000. Boston Partners acquired a new position in shares of Biogen in the fourth quarter worth about $302,815,000. Deutsche Bank AG purchased a new stake in shares of Biogen during the 2nd quarter worth about $193,165,000. Finally, Fred Alger Management LLC boosted its stake in shares of Biogen by 39,074.8% during the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock worth $140,576,000 after acquiring an additional 796,735 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Barclays increased their price target on Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 29th. Wedbush boosted their price objective on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, July 30th. Rothschild & Co Redburn upped their target price on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating on shares of Biogen in a research report on Tuesday, July 14th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $227.07.

Biogen Stock Performance

BIIB opened at $216.78 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm’s 50-day moving average price is $205.53 and its 200 day moving average price is $194.48. The firm has a market capitalization of $32.03 billion, a PE ratio of 38.37, a PEG ratio of 6.75 and a beta of 0.17. Biogen Inc. has a twelve month low of $131.52 and a twelve month high of $222.15.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the business posted $5.47 EPS. Biogen’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts expect that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.